Ultraviolet Blood Irradiation Successfully Aids in Treatment of Heart, Infection-related, Pregnancy-related, Immune, and Nervous System Disorders
Ultraviolet Blood Irradiation (UBI), a medical treatment with a rich history dating back nearly a century, has seen renewed interest in recent years. First introduced in the 1920s-1930s, this treatment involves exposing a small amount of a patient's blood to ultraviolet (UV) light outside the body and then returning it to the bloodstream [1][3][5].
Originally, UBI was extensively used in the 1930s through the 1950s for infections such as poliovirus and pneumonia. However, its use declined with the advent of antibiotics [1]. In modern times, due to growing antibiotic resistance and interest in natural or adjunct therapies, UBI has once again captured the attention of the medical community. It is currently applied as an immune-modulating therapy for conditions including chronic infections, autoimmune diseases, chronic fatigue, and psoriasis [1][5].
UBI is considered a non-invasive, generally safe treatment option that can help enhance immune function and oxygenation, potentially improving infection control and immune-related issues [3][5]. There have been hundreds of thousands of therapies reported, with over 200 medical studies supporting its safety and some clinical use over decades [2]. It is sometimes used alone to directly reduce pathogens in the blood or in combination with other treatments such as intravenous ozone therapy for enhanced antimicrobial effects [1].
Despite its promising potential, UBI remains an alternative or adjunctive therapy rather than a mainstream standard of care. While it has shown promise, particularly in immune stimulation and infection control, clear large-scale clinical trial evidence on its efficacy for many conditions is limited. Potential side effects and risks exist, so patient consideration and professional guidance are important before treatment, especially in complex diseases like cancer [3].
UBI has demonstrated remarkable efficacy against a wide range of conditions. For instance, a study on 50 patients with severe skull or brain injuries and concurrent pneumonia found that compared to 25 controls, their mortality and hospital stay were reduced, and an improved immune response was seen in their T-cell, IgA, and IgM levels [6]. Another study of 35 patients with moderate or severe COVID-19 found that UBI reduced their hospital stay by 7 days, prevented any of them from dying, and healed their lungs [7].
The history of UBI is marked by numerous success stories. In the 1940s, a man with multiple severe conditions, including brain and lung clots, pneumonia, and paralysis, made a near-instant recovery after receiving UBI [8]. Similarly, a 1942 study found that UBI successfully treated 20/20 early infections, 46/47 moderately advanced, and 17/36 moribund (on the verge of death) cases of acute pyogenic infections [9].
In America, UBI was widely adopted by hospitals but its decline was due to a flawed study published by the American Medical Association (AMA) in the 1940s [10]. However, in recent years, its use has primarily been found within integrative or functional medicine clinics as part of broader holistic care approaches.
In summary, UBI offers a non-invasive, immune-modulating alternative or adjunctive option especially where conventional therapies have limits or side effects [1][5]. Its rapid systemic response can cause patients on the brink of death to stabilize rapidly, as demonstrated by numerous historical cases. While clear large-scale clinical trial evidence on its efficacy for many conditions is limited, its safety and potential benefits make it a promising treatment worth further exploration.
References: [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389266/ [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783669/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032962/ [4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408504/ [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389266/ [6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829693/ [7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824366/ [8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610090/ [9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940035/ [10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934193/
- The medical treatment Ultraviolet Blood Irradiation (UBI) is deeply rooted in history, stemming from the 1920s-1930s.
- UBI has a rich history dating back nearly a century and has drawn renewed interest in recent years.
- UBI was originally used for infections such as poliovirus and pneumonia in the 1930s-1950s, but its use declined with the advent of antibiotics.
- In modern times, growing antibiotic resistance and interest in natural or adjunct therapies have brought UBI back into the spotlight.
- UBI is currently being applied as an immune-modulating therapy for conditions including chronic infections, autoimmune diseases, chronic fatigue, and psoriasis.
- UBI is a non-invasive, generally safe treatment option that enhances immune function and oxygenation, potentially improving infection control and immune-related issues.
- There have been hundreds of thousands of UBI therapies reported, with over 200 medical studies supporting its safety and some clinical use over decades.
- UBI is sometimes used alone or in combination with other treatments like intravenous ozone therapy for enhanced antimicrobial effects.
- UBI is an alternative or adjunctive therapy rather than a mainstream standard of care, although it holds potential in immune stimulation and infection control.
- Due to limited large-scale clinical trial evidence on its efficacy for many conditions, it is crucial to consider potential side effects and risks before treatment, especially in complex diseases like cancer.
- UBI has shown remarkable efficacy against a wide range of conditions.
- A study on 50 patients with severe skull or brain injuries and concurrent pneumonia found that UBI reduced their mortality and hospital stay and improved their immune response.
- Another study of 35 patients with moderate or severe COVID-19 found that UBI reduced their hospital stay, prevented any deaths, and healed their lungs.
- Historical cases demonstrate UBI's rapid systemic response, causing patients on the brink of death to stabilize rapidly.
- In the 1940s, UBI successfully treated numerous severe conditions, including brain and lung clots, pneumonia, and paralysis.
- In the 1940s, a man with multiple severe conditions made a near-instant recovery after receiving UBI.
- A 1942 study found that UBI successfully treated 20/20 early infections, 46/47 moderately advanced, and 17/36 moribund (on the verge of death) cases of acute pyogenic infections.
- UBI's decline in America was due to a flawed study published by the American Medical Association (AMA) in the 1940s.
- In recent years, UBI's use has primarily been found within integrative or functional medicine clinics as part of broader holistic care approaches.
- UBI offers a non-invasive, immune-modulating alternative or adjunctive option, particularly where conventional therapies have limitations or side effects.
- The history of UBI is marked by numerous success stories and holds great promise for further exploration and development.
- Reference [1] provides valuable information about UBI, including its history, applications, and safety.
- Reference [2] offers more insights into UBI's history, safety, and potential applications.
- Reference [3] provides an overview of UBI's safety, efficacy, and potential role in complex diseases like cancer.
- Reference [4] discusses the advantages and limitations of UBI as a treatment.
- Reference [5] provides additional information about UBI's history, applications, and safety.
- Reference [6] presents the results of a study demonstrating UBI's efficacy in reducing mortality and hospital stay for patients with severe skull or brain injuries and concurrent pneumonia.
- Reference [7] outlines the findings of a study on UBI's effects on the outcomes for patients with moderate or severe COVID-19.
- Reference [8] tells the story of a man's near-instant recovery after receiving UBI for multiple severe conditions.
- Reference [9] shares the findings of a 1942 study demonstrating the success of UBI in treating acute pyogenic infections.
- Reference [10] offers insights into the decline of UBI's use due to a flawed study published by the American Medical Association (AMA) in the 1940s.
